Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients (POSEIDON)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03406897|
Recruitment Status : Recruiting
First Posted : January 23, 2018
Last Update Posted : March 17, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 1 Hypoglycemia Diabetes Mellitus Diabetes, Autoimmune||Drug: Cholecalciferol Drug: Omega 3 fatty acid||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||56 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||
The study is a two-arm, open label, randomized trial. All four groups will receive standard intensive diabetes treatment with insulin and dietary management.
Group I: Fourteen (14) adults (18-65 years) of established T1D > 6 months (>180 days) and up to 10 years of T1D duration Group II: Fourteen (14) adults (18-65 years) of new-onset T1D diagnosed within last 6 months (≤ 180 days) Group III: Fourteen (14) children (6-17 years) of established T1D > 6 months (>180 days) and up to 10 years of T1D duration Group IV: Fourteen (14) children (6-17 years) of new-onset T1D diagnosed within last 6 months (≤ 180 days)
Participants in each group will be randomly assigned in a 1:1 ratio to receive either one year of high dose Omega-3 fatty acids and Vitamin D combination (Arm A) or Vitamin D alone (Arm B). Both arms will receive Vitamin D supplementation.
|Masking:||None (Open Label)|
|Official Title:||A Pilot, Safety and Feasibility Trial of High-Dose Omega-3 Fatty Acids and High-Dose Cholecalciferol (Vitamin D) Supplementation in Type 1 Diabetes|
|Actual Study Start Date :||July 23, 2018|
|Estimated Primary Completion Date :||September 2025|
|Estimated Study Completion Date :||December 2026|
Active Comparator: Omega-3 and Vitamin D Combination
The treatment arm A includes Omega-3 Fatty Acids and Cholecalciferol (Vitamin D) supplement.
Other Name: Vitamin D
Drug: Omega 3 fatty acid
Other Name: Omega 3
Active Comparator: Vitamin D Only
The treatment arm B (control group) will receive only Cholecalciferol (Vitamin D) supplement.
Other Name: Vitamin D
- MMTT (Mixed Meal Tolerance Test) [ Time Frame: Through study completion, and average of one year ]Stimulated (90 minute sample of a MMTT) C-peptide greater or equal to baseline level.
- Hemoglobin A1c Level Reduction [ Time Frame: Through study completion, and average of one year ]Reduction in HbA1c at the one year visit compared to baseline
- Reduction in Insulin Requirements [ Time Frame: Through study completion, and average of one year ]Reduction in insulin requirement at the 1 year visit compared to baseline
- Incidence of Adverse Events (AE) [ Time Frame: Through study completion, and average of one year ]Incidence of adverse events (AE) comparable to general diabetes population
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||6 Years to 65 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Patients must meet all of the following criteria to be eligible to participate in this study:
- Subjects or their parents if under 18 years old must be able to understand and provide informed consent.
- Males and females, 6-65 years of age.
- For new onset T1D subjects, ≤180 days from T1D diagnosis at the time of randomization with a MMTT stimulated C-peptide peak level ≥0.2 ng/ml prior to randomization.
- For established T1D subjects, >180 days and ≤10 years of T1D duration at the time of randomization and MMTT stimulated C-peptide peak level ≥0.2 ng/ml prior to randomization.
- Affected by T1D, according to ADA standard criteria, and confirmed by positivity of at least one T1D-associated autoantibody, to GAD65, IA-2, ZnT8, or insulin autoantibodies (if patient has been treated with insulin for less than 2 weeks).
- Female subjects of childbearing potential must have a negative pregnancy test upon study entry.
- Adequate venous access to support study required blood draws.
Potential participants must not meet any of the following exclusion criteria:
- Inability or unwillingness of a participant or their parents to give written informed consent or comply with study protocol.
- BMI>30 Kg/m2.
- Contra-indications to Omega-3 Fatty Acids and/or Vitamin-D (e.g., knowledge of hypersensitivity to drugs or its excipients, allergies with fish or shellfish etc.).
- Uncompensated heart failure, fluid overload, myocardial infarction or liver disease or severe impairment of a vital organ within the last 6 weeks before enrollment.
- Any sign or diagnosis of significant chronic active infection (e.g., hepatitis, tuberculosis, EBV, or CMV), or screening laboratory evidence consistent with a significant chronic active infection (such as positive for HIV, IGRA test for TB, or hepatitis B-C).
- Ongoing acute infections, e.g., acute respiratory tract urinary tract, or gastrointestinal tract infections.
- Subjects on weight altering medications, such as Orlistat.
- Subjects with eating disorders
- Ongoing or anticipated use of diabetes medications other than insulin.
- Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within prior 7 days of screening.
- People who chronically take drugs that affect bleeding time, such as anticoagulants ("blood thinners") or nonsteroidal anti-inflammatory drugs (NSAIDs), will not qualify to enroll in the study.
- Recent recipient of any licensed or investigational live attenuated vaccine(s) within 6 weeks of randomization.
- Use of investigational drugs within 4 months of participation.
- Concomitant therapy with immunosuppressive drugs, immunomodulators, or cytotoxic agents, or previous therapy less than 3 months from randomization.
- History or diagnosis of malignancy.
- History of gastroparesis or other severe gastrointestinal disease.
- History or diagnosis of malignancy with the exception of a history of localized basal or squamous cell carcinoma. There is conflicting evidence about whether omega-3 fatty acids found in seafood and fish oil might increase the risk of prostate cancer. Until additional research on the association of omega-3 consumption and prostate cancer risk is conducted, subjects with family history of prostate cancer in a first-degree relative will be excluded from the study.
- Presence of an allograft.
- AST, ALT or Alkaline Phosphatase >2 times upper limit of normal or total bilirubin >1.5 times upper limit of normal.
- History of a mental illness deemed to be clinically unstable or any situation that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
- History of illicit drug or alcohol abuse.
- Pregnancy or ongoing breastfeeding for women; unwillingness or inability of both females and males of childbearing age to use a reliable and effective form of contraception, for the entire duration of the study.
- Past or current medical problems, or findings from physical examination, or laboratory testing, that are not listed above which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained.
- All patients who have coagulation, bleeding, or blood disorders will be excluded due to the effect of high dose of Omega 3 Fatty Acids on coagulation and bleeding process.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03406897
|Contact: David A Baidal, M.D.||(305) 243-7740 ext email@example.com|
|Contact: Rodolfo Alejandro, M.D.||(305) 243-5324||RAlejand@med.miami.edu|
|United States, Florida|
|Diabetes Research Institute, University of Miami Miller School of Medicine||Recruiting|
|Miami, Florida, United States, 33136|
|Contact: Rodolfo Alejandro, M.D. 305-243-5324 firstname.lastname@example.org|
|Contact: David A Baidal, M.D. (305) 243-7740 email@example.com|
|Principal Investigator: Rodolfo Alejandro, M.D.|
|Principal Investigator: David A Baidal, M.D.|
|Study Director:||Camillo Ricordi, M.D.||Professor and Center Director of Diabetes Research Institute|
|Responsible Party:||Rodolfo Alejandro, Professor of Medicine, University of Miami|
|Other Study ID Numbers:||
|First Posted:||January 23, 2018 Key Record Dates|
|Last Update Posted:||March 17, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Endocrine System Diseases
Immune System Diseases
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents